Study To Evaluate Treating Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01089686|
Recruitment Status : Terminated
First Posted : March 18, 2010
Last Update Posted : March 7, 2012
|Condition or disease||Intervention/treatment||Phase|
|Multiple Sclerosis||Procedure: Venoplasty Procedure: Sham procedure (non-treatment)||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||2 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Outcomes Assessor)|
|Official Title:||Utility of Chronic Cerebrospinal Venous Insufficiency Percutaneous Angioplasty for Multiple Sclerosis: The Albany Vascular Group Study (Liberation Study)|
|Study Start Date :||August 2010|
|Estimated Primary Completion Date :||October 2012|
|Estimated Study Completion Date :||October 2012|
Active Comparator: Venoplasty (treatment)
Patients will be randomized to treatment or non-treatment arm with a 2:1 ratio. Patients who meet the inclusion/exclusion criteria and who are randomized to the treatment arm of the study will receive venoplasty at the time of the diagnostic venogram.
Venous access is obtained from the groin through the femoral vein. The catheter will be advanced into the veins in the neck and chest. Angiographic images will be taken of the extracranial venous system as well as the azygous vein. These images will be used to confirm CCSVI. Venoplasty is performed by inserting an additional catheter with a balloon at the tip. The balloon will be inflated to open the vessel. Once dilation of the vessel is confirmed, the venous sheath will be removed and manual compression applied to the groin access.
Sham Comparator: Sham procedure (non-treatment)
Patients will be randomized to treatment or non-treatment with a 2:1 ratio. Patients who meet the inclusion/exclusion criteria and who are randomized to the non-treatment arm of the study will receive the diagnostic venogram only.
Procedure: Sham procedure (non-treatment)
Venous access is obtained from the groin through the femoral vein. The catheter will be advanced into the veins in the neck and chest. Angiographic images will be taken of the extracranial venous system as well as the azygous vein. These images will be used to confirm CCSVI. Since the patient has been randomized to the non-treatment arm of the trial, the procedure will end without venoplasty. After completion of the diagnostic venogram, the venous sheath will be removed and manual compression applied to the groin access.
- Incidence of major adverse events [ Time Frame: 30 days ]The evaluation of safety will be defined as the incidence of major adverse events at 30 days following the index procedure. The evaluation of feasibility and efficacy will be determined by those patients that do not have more than 50 percent restenosis within the 30 day time frame.
- Neurological assessment of MS [ Time Frame: 1 year ]An independant neurologist will assess the number of MS attacks that have occurred during one year follow up period.
- MRI/MRA evaluation of MS lesions, recommended [ Time Frame: 1 year ]Evaluation of imaging to reveal local iron content, change in MS lesions and oxygen saturation changes using conventional MRA/MRI methods by an independant radiologist.
- Mortality [ Time Frame: 1 year ]All cause mortality will be evaluated through one year.
- Major adverse events [ Time Frame: 1 year ]Incidence of all major adverse events will be collected for one year.
- Identification of central venous stenosis [ Time Frame: 1 year ]Evaluation of the correlation between MRV, Duplex Ultrasound and Venogram in identifying central venous stenosis.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01089686
|United States, New York|
|The Vascular Group, PLLC, The Vascular Health Pavillion|
|Albany, New York, United States, 12205|
|Principal Investigator:||Manish Mehta, MD, MPH||The Vascular Group, PLLC|